Suven Life Sciences gets product patents from India, South Korea
New Delhi: Suven Life Sciences has secured a product patent each from India and South Korea for treatment of disorders associated with neurodegenerative diseases.
The patents are valid through 2029 and 2033 respectively, the company said in a BSE filing.
"We are pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena, that is being developed for cognitive disorders with high unmet medical need with a huge market potential globally," Suven Life CEO Venkat Jasti said.
Suven Life said the granted claims of the patents are being developed as therapeutic agents and useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Parkinson, and Schizophrenia.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd